Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

Lung cancer is the third most common cancer in men and women ... attached to chemotherapy drugs that then attach themselves ...

It occurs when abnormal cells in the prostate gland grow and divide uncontrollably ... often dismissing their symptoms or ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

A Wigan grandad who died from cancer has left a lasting legacy which could make a real difference for other patients and ...